HOLX vs. INCY

Last updated Apr 1, 2026

Compare and contrast key facts about Hologic, Inc. (HOLX) and Incyte Corporation (INCY).

Performance

HOLX vs. INCY - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Hologic, Inc. (HOLX) and Incyte Corporation (INCY). The values are adjusted to include any dividend payments, if applicable.

HOLX vs. INCY - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018	2017
HOLX Hologic, Inc.	1.48%	3.33%	0.90%	-4.49%	-2.29%	5.12%	39.49%	27.03%	-3.86%	6.56%
INCY Incyte Corporation	-4.71%	43.00%	10.00%	-21.83%	9.43%	-15.61%	-0.39%	37.32%	-32.86%	-5.55%

Fundamentals

Market Cap HOLX : $17.07B INCY : $19.27B
EPS HOLX : $2.41 INCY : $6.38
PE Ratio HOLX : 31.37 INCY : 14.75
PS Ratio HOLX : 4.13 INCY : 3.69
PB Ratio HOLX : 3.26 INCY : 3.73
Total Revenue (TTM) HOLX : $4.13B INCY : $5.14B
Gross Profit (TTM) HOLX : $2.18B INCY : $4.74B
EBITDA (TTM) HOLX : $1.01B INCY : $1.68B

Returns By Period

In the year-to-date period, HOLX achieves a 1.48% return, which is significantly higher than INCY's -4.71% return. Over the past 10 years, HOLX has outperformed INCY with an annualized return of 8.13%, while INCY has yielded a comparatively lower 2.53% annualized return.

HOLX

• 1D: 0.05%
• 1M: 0.31%
• YTD: 1.48%
• 6M: 12.00%
• 1Y: 22.37%
• 3Y*: -2.16%
• 5Y*: 0.33%
• 10Y*: 8.13%

INCY

• 1D: 4.20%
• 1M: -7.06%
• YTD: -4.71%
• 6M: 10.98%
• 1Y: 55.44%
• 3Y*: 9.20%
• 5Y*: 2.54%
• 10Y*: 2.53%

*Multi-year figures are annualized to reflect compound growth (CAGR)

Return for Risk

HOLX vs. INCY — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

HOLX

HOLX Risk / Return Rank: 75
HOLX Sharpe Ratio Rank: 72
HOLX Sortino Ratio Rank: 72
HOLX Omega Ratio Rank: 76
HOLX Calmar Ratio Rank: 73
HOLX Martin Ratio Rank: 82

INCY

INCY Risk / Return Rank: 85
INCY Sharpe Ratio Rank: 87
INCY Sortino Ratio Rank: 84
INCY Omega Ratio Rank: 82
INCY Calmar Ratio Rank: 86
INCY Martin Ratio Rank: 87

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

HOLX vs. INCY - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Hologic, Inc. (HOLX) and Incyte Corporation (INCY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	HOLX	INCY	Difference
Sharpe ratio Return per unit of total volatility	0.90	1.64	-0.74
Sortino ratio Return per unit of downside risk	1.67	2.31	-0.64
Omega ratio Gain probability vs. loss probability	1.25	1.30	-0.04
Calmar ratio Return relative to maximum drawdown	1.59	3.02	-1.43
Martin ratio Return relative to average drawdown	6.62	8.51	-1.89
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

HOLX vs. INCY - Sharpe Ratio Comparison

The current HOLX Sharpe Ratio is 0.90, which is lower than the INCY Sharpe Ratio of 1.64. The chart below compares the historical Sharpe Ratios of HOLX and INCY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

Sharpe Ratios by Period

	HOLX	INCY	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	0.90	1.64	-0.74
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.01	0.09	-0.07
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	0.31	0.07	+0.23
Sharpe Ratio (All Time) Calculated using the full available price history	0.19	0.21	-0.02

Correlation

The correlation between HOLX and INCY is 0.27, which is considered to be low. This implies their price changes are not closely related. A low correlation is generally favorable for portfolio diversification, as it helps to reduce overall risk by spreading it across multiple assets with different performance patterns.

Dividends

HOLX vs. INCY - Dividend Comparison

Neither HOLX nor INCY has paid dividends to shareholders.

Tickers have no history of dividend payments

Drawdowns

HOLX vs. INCY - Drawdown Comparison

The maximum HOLX drawdown since its inception was -93.75%, roughly equal to the maximum INCY drawdown of -98.54%. Use the drawdown chart below to compare losses from any high point for HOLX and INCY.

Drawdown Indicators

	HOLX	INCY	Difference
Max Drawdown Largest peak-to-trough decline	-93.75%	-98.54%	+4.79%
Max Drawdown (1Y) Largest decline over 1 year	-14.52%	-18.33%	+3.81%
Max Drawdown (5Y) Largest decline over 5 years	-39.85%	-41.53%	+1.68%
Max Drawdown (10Y) Largest decline over 10 years	-46.24%	-66.47%	+20.23%
Current Drawdown Current decline from peak	-13.78%	-38.35%	+24.57%
Average Drawdown Average peak-to-trough decline	-40.25%	-60.04%	+19.79%
Ulcer Index Depth and duration of drawdowns from previous peaks	3.51%	6.50%	-2.99%

Volatility

HOLX vs. INCY - Volatility Comparison

The current volatility for Hologic, Inc. (HOLX) is 0.75%, while Incyte Corporation (INCY) has a volatility of 7.78%. This indicates that HOLX experiences smaller price fluctuations and is considered to be less risky than INCY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	HOLX	INCY	Difference
Volatility (1M) Calculated over the trailing 1-month period	0.75%	7.78%	-7.03%
Volatility (6M) Calculated over the trailing 6-month period	7.02%	23.78%	-16.76%
Volatility (1Y) Calculated over the trailing 1-year period	24.91%	33.95%	-9.04%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	23.12%	29.17%	-6.05%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	26.51%	34.60%	-8.09%

Financials

HOLX vs. INCY - Profitability Comparison

The chart below illustrates the profitability comparison between Hologic, Inc. and Incyte Corporation over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

HOLX - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Hologic, Inc. reported a gross profit of 586.40M and revenue of 1.05B. Therefore, the gross margin over that period was 56.0%.

INCY - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Apr 2026, Incyte Corporation reported a gross profit of 1.39B and revenue of 1.51B. Therefore, the gross margin over that period was 92.0%.

HOLX - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Hologic, Inc. reported an operating income of 237.00M and revenue of 1.05B, resulting in an operating margin of 22.6%.

INCY - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Apr 2026, Incyte Corporation reported an operating income of 543.78M and revenue of 1.51B, resulting in an operating margin of 36.1%.

HOLX - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Hologic, Inc. reported a net income of 179.10M and revenue of 1.05B, resulting in a net margin of 17.1%.

INCY - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Apr 2026, Incyte Corporation reported a net income of 299.28M and revenue of 1.51B, resulting in a net margin of 19.9%.